Abstract: The present compositions advantageously treat hyperemia with substantially no added irritation to the eye. In one embodiment, the compositions include an ophthalmically acceptable carrier component, a vasoconstrictor component in an amount effective to treat hyperemia when the composition is administered to an eye, and a polyanionic component in an amount effective to provide lubrication to an eye when the compositions are administered to the eye.

Abstract: A partially hydrated lens is provided for implantation into a cornea. The partially hydrated lens has a water content less than the water content of the cornea, resulting in an osmotic pressure differential between the lens and the cornea which improves adhesion between the lens and the corneal tissue. It also causes the lens to expand and flatten when implanted, and to naturally center itself while flattening. In the preferred embodiment of the invention, the lens is maintained in its partially hydrated state by storage in a hypertonic hydration medium.

Abstract: An intraocular lens (IOL) insertion apparatus for implanting acrylic IOLs through smaller incisions. The insertion apparatus includes an insertion cartridge that receives the IOL and cooperates with a handpiece. The cartridge includes a longitudinal lumen from a loading chamber to an open distal mouth that gradually narrows in dimension so as to fold the acrylic IOL to a dimension of less than about 2.0 mm. The cartridge is made of a polymer, such as polypropylene, that includes a lubricity enhancing component concentrated at surfaces by a blooming process. A push rod in the handpiece enters the loading chamber of the cartridge and urges the IOL therethrough. A distal tip of the push rod has an irregular shape, such as a rounded trapezoidal, and has a maximum dimension slightly less than the inner diameter of the open distal mouth of the cartridge. The distal tip of the push rod may have a relief channel on one side that accommodates a trailing haptic of the IOL.

Abstract: A compound of formula I 1

Abstract: The present invention provides for methods of treating cardiovascular diseases in a mammal. The methods include a step of administering an effective amount of a botulinum toxin directly to a blood vessel of a mammal thereby treating a cardiovascular disease.

Abstract: A skin topographical method for quantifying pharmacodynamic parameters of a paralytic effect of a Clostridial toxin, such as a botulinum toxin upon a muscle, such as a frontalis muscle.

Abstract: An intraocular lens having an ultrathin and highly pliable optic and relatively more rigid fixation members extending outward therefrom. The optic desirably includes a flange to which a common arm of a pair of joined fixation members attaches. The fixation members extend on opposite sides of the optic in U-shaped flex portions spanning a distance larger than the diameter of the optic. The fixation members may be flexed inward so as to overlap within the diameter of the optic and define an insertion profile of less than about 5 mm. For anterior implantation, four relatively evenly circumferentially spaced pods are provided by the pair of fixation members. The optic center desirably has a thickness of less than about 0.5 mm for meniscus type optics, and may be made of silicone, hydrophilic acrylic, or hydrophobic acrylic. The fixation members have a thickness of about 0.25 mm and are desirably made of poly methyl methacrylate (PMMA) or polyether sulfone.

Abstract: Apparatus for inserting intraocular lenses (IOLs) into eyes are disclosed. The apparatus comprises an insertion tube, and an injector rod having a distal tip capable of engaging an intraocular lens. A guide assembly is provided to direct the distal tip of the rod radially outwardly as it moves distally through the insertion tube. The radial movement of the tip is controlled such that the tip contacts a proximal edge, rather than a fold, of the IOL. The tip exerts little or no pressure on the bottom wall of the IOL cartridge, with any incidental pressure varying as the tip moves distally. In one embodiment, the guide assembly also includes a component for allowing the tip to return upward after contacting the IOL, thus decreasing or eliminating the pressure on the wall as the rod tip continues through a narrower diameter exit portion of the cartridge. Methods for inserting an IOL into an eye using such apparatus are also disclosed and are within the scope of the present invention.

Abstract: Method for treating dermal pre-melanoma conditions which include administering an effective amount of a photosensitive agent to a dermal pre-melanoma cell and activating the photosensitive agent, thereby treating a dermal pre-melanoma condition.

Abstract: Apparatus and methods for protecting the edge geometry of an intraocular lens during polishing are disclosed. The apparatus comprises a protective device having a cavity configured to receive the lens and an annular peripheral portion for surrounding and protecting at least one edge corner of the lens. In one embodiment, the peripheral portion has a constant inner diameter and receives the lens in an interference fit. In another embodiment, the lens is trapped between flanges which extend radially inwardly from the peripheral portion. A lens that is encased in the protective device will have a polished central portion and an unpolished peripheral portion after the polishing process has been completed and the protective device has been removed.

Abstract: The present invention relates to methods for treating neurogenic inflammation pain. The methods include administering an effective amount of a composition which includes a botulinum toxin component and a substance P component to a patient, thereby treating the neurogenic inflammation pain.

Abstract: Compositions which include therapeutically active components, solubility enhancing components other than cyclodextrins, and oxy-chloro components, wherein the oxy-chloro components are substantially effective as preservatives. In one embodiment, the oxy-chloro components are useful for preserving the therapeutically active components. In one embodiment, the oxy-chloro components include chlorite components. In a useful embodiment, the solubility enhancing components include carboxymethylcellulose.

Abstract: Methods and compositions for inhibiting or preventing spermatogenesis in a male mammal. Also disclosed are compounds and formulations for use in such methods.

Abstract: Methods for modulating the activity of the mammalian BAR/FXR receptor. The methods include methods of treating a hypocholesterolemic mammal comprising contacting the mammal with synthetic compounds able to modulate an activity characteristic of the BAR/FXR receptor. Other methods include a method of treating colon cancer in a mammal comprising administering a compound having a BAR/FXR antagonistic activity.

Abstract: The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the general formula I; 1

Abstract: An binocular lens system for improving the vision of a patient including first and second ophthalmic lenses. Each of these lenses is adapted for implantation in an eye or to be disposed on or in the cornea. The first lens has a first baseline diopter power for distance vision correction and the second ophthalmic lens has a second baseline diopter power for other than distance vision correction. The ophthalmic lenses may be intraocular lenses which are implanted in the eyes of a patient or has natural lenses or following removal of the natural lenses.

Abstract: Pharmaceutical conjugates comprising a therapeutic component and an efficacy enhancing component that enhances the pharmacokinetic disposition of the therapeutic component is disclosed. In one embodiment, therapeutic component is joined to an efficacy enhancing component by a linker. In one embodiment, the therapeutic component and the efficacy enhancing component disassociate under physiolocal conditions, preferably near the site where the therapeutic component may exert a therapeutic effect.

Abstract: Methods for measuring retinal damage resulting from an injury include calculating the slope of retinal thickness from the injury site to the periphery of the site. A shallower slope of retinal thickness correlates with a greater degree of damage resulting from the injury. The methods may also be useful to screen pharmaceuticals for potential neuroprotective effects against retinal injuries.

Abstract: Compositions including a quinolone component, such as ofloxacin, having fungistatic activity in the compositions, present in an amount effective as an antibiotic when the composition is placed in a mammalian eye, a NSAID component present in an amount to reduce inflammation or pain when the composition is placed in the eye, and a carrier component in an amount effective to act as a carrier for the quinolone component and NSAID component are provided. Methods of using the present compositions, for example, to resolve microbial infections and/or to reduce inflammation and/or pain in a mammalian eye are included within the scope of the present invention. Methods for treating corneal injuries are also included. In addition, methods for treating ocular infections, for example, corneal infections, are included.

Abstract: A method of treating ocular hypotension, hypertension, hemorrhage, myocardial ischemia, angina pectoris, coronary contraction, cerebrovascular contraction after subarachnoidal hemorrhage, cerebral hemorrhage and asthma which comprises administering to a mammal suffering therefrom a therapeutically effective amount of a thromboxane ligand which is a compound formula I, 1